These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15084980)

  • 1. Development of immunotherapy for pancreatic cancer.
    Kawakami Y; Okada T; Akada M
    Pancreas; 2004 Apr; 28(3):320-5. PubMed ID: 15084980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of human tumor antigens recognized by T-cells and their use for immunotherapy.
    Kawakami Y
    Int J Hematol; 2003 Jun; 77(5):427-34. PubMed ID: 12841379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging trends in the immunotherapy of pancreatic cancer.
    Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
    Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of immunotherapy for cancer: lessons from melanoma research].
    Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Apr; 27(2):87-98. PubMed ID: 15164929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
    Leko V; Rosenberg SA
    Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic redirection of T cells for cancer therapy.
    Westwood JA; Kershaw MH
    J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for adoptive T cell therapy.
    Yee C; Riddell SR; Greenberg PD
    Curr Opin Immunol; 1997 Oct; 9(5):702-8. PubMed ID: 9368780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
    Gautam SK; Kumar S; Dam V; Ghersi D; Jain M; Batra SK
    Semin Immunol; 2020 Feb; 47():101391. PubMed ID: 31952903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
    Liu Z; Guo B; Lopez RD
    J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of immunotherapy in oncology].
    Zielinski C
    Acta Med Austriaca; 1991; 18(1):20-4. PubMed ID: 1713730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic strategies for hepatocellular carcinoma.
    Butterfield LH
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S232-41. PubMed ID: 15508089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
    Rosenberg SA
    Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular targets for development of cancer immunotherapy].
    Kawakami Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
    [No Abstract]   [Full Text] [Related]  

  • 17. The promise of T-lymphocyte immunotherapy for the treatment of malignant disease.
    Thomas AK; June CH
    Cancer J; 2001; 7 Suppl 2():S67-75. PubMed ID: 11777267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in Japanese patients with advanced cancer.
    Araki K; Noguchi Y; Hirouchi T; Yoshikawa E; Kataoka S; Silverni L; Miyazawa H; Kuzuhara H; Suzuki C; Shimada Y; Hamasato S; Maeda N; Shimamura Y; Ogawa Y; Ohtsuki Y; Fujimoto S
    Int J Oncol; 2000 Dec; 17(6):1107-18. PubMed ID: 11078795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.